LevitasBio Announces the LeviCell EOS System: A New Era in Sample Processing and Characterization
LevitasBio, Inc. today unveiled the LeviCell™ EOS System, their next generation solution for cell separation and enrichment, featuring higher throughput and simultaneous targeted selection of viable cells. Utilizing field proven Levitation Technology, researchers can now effectively scale their experiments up to 16x and process up to 40 million cells per run. The LeviCell EOS System debuts, along with new LeviPrep and LeviSelect product lines for tissue dissociation and targeted cellular selection, at the 2022 American Association for Cancer Research General Meeting held April 8-13 in New Orleans, Louisiana.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220407005408/en/
Unprecedented Sample Throughput and Scalability
LevitasBio first revolutionized sample preparation in 2020 with the launch of the LeviCell System, which introduced researchers to a gentle, fast, and unbiased method to separate and enrich cells of interest via magnetic levitation. Less than two years later, LevitasBio has addressed researchers’ oft stated desire for scalability, both in the quantity of samples and cells that can be levitated and accessed. The new LeviCell EOS system increases sample throughput by four-fold and enables up to four LeviCell EOS modules to be interconnected and independently controlled, increasing total scalability by 16x. Researchers can now accelerate their discoveries with unprecedented sample processing power and insights.
A New Era in Sample Processing
The LeviCell EOS system introduces several new features that enhance unbiased sample processing to optimize the study of natural biology. First is an embedded thermal control system, which allow users to select from a range of pre-defined temperatures, ensuring samples are processed at ideal temperatures to maintain cellular states.
Additionally, an advanced, fully reticulated imaging system enables powerful, real-time sample characterization analytics during processing. Important insights such as fractionation, cell counts, viability assessment, and quality measurements, can be reviewed real-time, empowering researchers to make informed decisions on how to best utilize their enriched samples in downstream studies.
Finally, the LeviCell EOS system delivers unprecedented flexibility with a modular and interchangeable EOS Magnetic Core. A growing family of selectable core modules will enable a broad range of specifically optimized applications on a single platform.
“We are changing the landscape of how researchers conduct their experiments,” says Martin Pieprzyk, CEO of LevitasBio. “The new LeviCell EOS system paves the way for fully integrated approaches to sample processing and accurate characterization at scaled throughputs. This marks a profound shift in how scientists work with their samples.”
LevitasBio has pioneered a new and powerful method of cellular enrichment and analysis. Utilizing proprietary Levitation Technology, our LeviCell platform can accurately and gently detect, quantify, enrich, and test cells. Our unbiased, label-free method can detect cell type and state with minimal time and handling, and has been adopted across a broad range of critical applications, including single cell multi-omics, CRISPR, and cell line development.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Anterra Capital: Pandemic and Food Price Inflation Fuel Investor Interest to Accelerate Transformation of the Food and Ag Sector18.5.2022 07:00:00 CEST | Press release
A crushing pandemic and, more recently, the Ukraine war have convinced investors more than ever that the world needs to radically change how it produces, distributes and consumes food, says Adam Anders, managing partner of the international food and agriculture specialist venture capital firm Anterra Capital (“Anterra”). Anders: “The pandemic highlighted the fragility and adverse health impacts of our current food system: soaring prices, empty shelves in stores; the fact that unhealthy diets are a major risk factor for getting Covid; that the way we treat farm animals could trigger the next pandemic. Post our final closing, the devastating impact of the Ukraine War on the global food supply has increased the awareness among investors even further. This, plus our focus on deploying proven biotech and digital solutions to shake up the lagging Food and Ag-sector, go a long way in explaining the higher than expected interest in our second fund.” Anterra is proud to announce the closing of
US Streaming Technology Giant Conviva Launches Full-Scale Continuous Measurement Analytics in Japan18.5.2022 03:00:00 CEST | Press release
Conviva (Headquartered at Foster City, California, USA; Japan Office: Chiyoda-ku, Tokyo; hereinafter referred to as Conviva or the Company), which provides continuous measurement analytics through real-time, server side sessionization of video streaming data, today announced the opening of the Japan office, which will serve as a base for sales and customer support in the rapidly-growing Japanese market. The Company also released a current State of Streaming Report for Japan highlighting key streaming trends in the market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517006275/en/ Conviva State of Streaming Japan Report (Graphic: Business Wire) “Conviva invented continuous measurement analytics for streaming video and has been driving the development of the global market including Japan with over 58 technology patents over the past decade,” comments Conviva CEO Keith Zubchevich. “Today, we are pleased to announce the est
Starr Insurance Companies Expands in Thailand17.5.2022 22:33:00 CEST | Press release
Starr Insurance Companies (Starr) announced an agreement with FPG Insurance Holdings Limited (HK) (FPG) and local Thai shareholders to purchase FPG Insurance Public Company Limited (FPG Thailand), a Thai non-life insurance company, together with local Thai parties. Starr’s investment will be held by its Bermuda insurance company, Starr Insurance & Reinsurance Limited. The transaction is expected to close in the second quarter of 2022, subject to certain customary closing conditions, including any necessary regulatory approvals. “Thailand is an important, fast-growing insurance market — one of the cornerstones of the Southeast Asia economy,” said Maurice R. Greenberg, Starr’s Chairman & CEO. “Asia is both commercially and culturally important to Starr, as we trace our roots to an American-owned company founded in Shanghai more than 100 years ago. We look forward to serving the needs of local Thai companies and consumers through this new insurance capability.” David Zuellig, FPG regional
Emendo Biotherapeutics’ next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE -related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting17.5.2022 22:15:00 CEST | Press release
Emendo Biotherapeutics presented the results of its next generation CRISPR-based gene editing approaches for several indications in an oral presentation and three posters at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held May 16-19, 2022, in Washington, D.C. Emendo presented pre-clinical data for the treatment of ELANE-related Severe Congenital Neutropenia using an allele-specific editing approach, demonstrating the power of Emendo’s dual technology platforms that enable the development of a highly specific editing composition that demonstrates no off-targets and complete allele specificity. Significantly, the lack of off-target achieved by Emendo’s engineered and optimized OMNI nuclease also eliminated any translocations. Edited patient derived CD34+ cells differentiated normally into neutrophils both in-vitro and in-vivo, showing full engraftment and reconstitution of all blood lineages, as required for the desired therapeutic effect. “ELANE-based
Piper Sandler Advises PETRONAS Chemicals Group Berhad on Acquisition of Perstorp17.5.2022 19:59:00 CEST | Press release
Piper Sandler & Co. chemicals investment banking announced today that it has advised PETRONAS Chemicals Group Berhad (PCG) on its acquisition of Perstorp Holding AB. The transaction Enterprise Value is €2,300 million and base purchase price, less adjusted net debt, is €1,538 million. It is expected to close in Q3 2022 subject to customary closing conditions. PCG is the leading integrated chemicals producer in Malaysia and one of the largest in Southeast Asia. It operates a number of world-class production sites, which are fully vertically integrated from feedstock to downstream end-products. With a total combined production capacity of 12.8 million metric tons per annum (mtpa), it is involved primarily in manufacturing, marketing, and selling a diversified range of chemical products, including olefins, polymers, fertilizers, methanol and other basic chemicals and derivative products. Listed on Bursa Malaysia in 2010 and with more than three decades of experience in the chemicals indust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom